Financial Data and Key Metrics Changes - Revenues for Q2 2019 were $7.5 million, up 23% from Q2 2018, and significantly above Q1 2019 revenues of $5.4 million [20][21] - Gross profit for Q2 2019 was $4.9 million, representing 66.1% of revenues, compared to $3.9 million or 65.1% for Q2 2018 [20][21] - Net income for Q2 2019 was $0.1 million or $0.01 per diluted share, compared to a net loss of $0.5 million or $0.04 per share for Q2 2018 [25] Business Line Data and Key Metrics Changes - The company shipped 22 systems in total during Q2 2019, including 17 SRT-100 Vision systems, indicating a recovery in sales [7][20] - The SRT-100 Vision system sales were a significant contributor to revenue growth, with a focus on expanding the customer base to large dermatology practices and hospital centers [9][32] Market Data and Key Metrics Changes - The company is targeting a market consisting of approximately 14,000 dermatologists and 1,000 Mohs surgeons in the U.S., representing over 7,500 offices [32] - The inclusion of SRT products in Premier Healthcare Alliance's approved products list is expected to enhance market penetration [13] Company Strategy and Development Direction - The company is focused on expanding its SRT customer base and enhancing its product offerings, including the unique Sentinel IP product for asset management [10][12] - The Sculptura Modulated Robotic Brachytherapy system is being actively marketed, with collaborations with medical institutions to support its launch [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of the year, citing a resumption of sales to a key customer and ongoing efforts to work with multisite customers [32] - The company anticipates positive developments in reimbursement codes, particularly with the main code 77401 scheduled for revaluation in 2021 [17][19] Other Important Information - Cash and investments as of June 30, 2019, were $16.8 million, an increase from $15.4 million at the end of 2018, with no outstanding borrowings [27] - The company expects to increase sales and marketing expenses in Q3 2019 due to trade show costs and the Sculptura launch [22] Q&A Session Summary Question: Changes with the large turnkey partner - Management confirmed the renewal of the contract with SkinCure and ongoing discussions regarding terms and conditions [38] Question: Resolution of DOJ CID from a few years back - Management reported no follow-up news or issues related to the DOJ CID [44] Question: Timeline for Sculptura data from institutions - Management indicated ongoing collaboration with UPenn and efforts to gather data ahead of the ASTRO conference [45][46] Question: Expectations for aesthetic products from Israel - Management stated that aesthetic products are on track for FDA approval, with a focus on quality and differentiation [52] Question: Current reimbursement rates and future expectations - Current reimbursement for SRT is approximately $2,000 to $2,100 for an episode of care, with expectations for revaluation in 2021 [57][58]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1647271 (State ...

Sensus Healthcare's (NASDAQ:SRTS) Q1 2019 Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Arthur Levine - CFO Joseph Sardano - Chairman, CEO & President Kim Golodetz - SVP and Principal Conference Call Participants Brendan Popson - Northcoast Research Partners, LLC Christopher Paul McGinnis - Sidoti & Company, LLC Operator Good day and welcome to the Sensus Healthcare First Quarter Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to tu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ____________ Commission File Number: 001-37714 Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1647271 (State or ot ...

Sensus Healthcare (NASDAQ:SRTS) Q4 2018 Earnings Conference Call February 14, 2019 4:30 PM ET Company Participants Kim Golodetz – LHA Investor Relations Joe Sardano – Chief Executive Officer Arthur Levine – Chief Financial Officer Conference Call Participants Alex Nowak – Craig-Hallum Capital Group Andrew D’Silva – B. Riley FBR Anthony Vendetti – Maxim Group Ben Haynor – Alliance Global Partners Scott Henry – ROTH Capital Yi Chen – H.C. Wainwright Marcel Herbst – Herbst Capital Management Operator Good afte ...